Title: Controlled trial of lamotrigine (Lamictal®) for treatment-resistant partial seizures
Abstract: Acta Neurologica ScandinavicaVolume 94, Issue 4 p. 247-252 Controlled trial of lamotrigine (Lamictal®) for treatment-resistant partial seizures J. Boas, Corresponding Author J. Boas Glostrup Hospital, Copenhagen*Glostrup Hospital, DK-2600, Copenhagen, DenmarkSearch for more papers by this authorM. Dam, M. Dam Hvidovre Hospital, CopenhagenSearch for more papers by this authorM. L. Friis, M. L. Friis Odense University Hospital, CopenhagenSearch for more papers by this authorO. Kristensen, O. Kristensen Odense University Hospital, CopenhagenSearch for more papers by this authorB. Pedersen, B. Pedersen Aalborg Hospital, Aalborg, DenmarkSearch for more papers by this authorJ. Gallagher, J. Gallagher GlaxoWellcome Ltd, Beckenham, EnglandSearch for more papers by this author J. Boas, Corresponding Author J. Boas Glostrup Hospital, Copenhagen*Glostrup Hospital, DK-2600, Copenhagen, DenmarkSearch for more papers by this authorM. Dam, M. Dam Hvidovre Hospital, CopenhagenSearch for more papers by this authorM. L. Friis, M. L. Friis Odense University Hospital, CopenhagenSearch for more papers by this authorO. Kristensen, O. Kristensen Odense University Hospital, CopenhagenSearch for more papers by this authorB. Pedersen, B. Pedersen Aalborg Hospital, Aalborg, DenmarkSearch for more papers by this authorJ. Gallagher, J. Gallagher GlaxoWellcome Ltd, Beckenham, EnglandSearch for more papers by this author First published: October 1996 https://doi.org/10.1111/j.1600-0404.1996.tb07060.xCitations: 27AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract The antiepileptic effect of lamotrigine (Lamictal®) was assessed in a double-blind, placebo-controlled, crossover trial in 56 adult patients with refractory partial seizures. Lamotrigine or placebo was added to the patients' existing antiepileptic drugs (AEDs). The dose of lamotrigine varied from 75 to 400 mg daily. Thirty-eight patients completed the trial and 7 withdrew because of adverse experiences. There was a statistically significant reduction in seizure counts on lamotrigine compared with placebo for total seizures (30.3% reduction, 95% CI 8.4%, 47.0%), complex partial seizures (29.2.% reduction, 95% CI 3.8%, 47.9%) and secondary generalised seizures (37.9%, CI 18.9%, 52.4%). The analysis of total seizure days showed a similar significant reduction during lamotrigine treatment for the same seizure categories. There was no statistically significant difference in reporting of adverse events between lamotrigine and placebo except for dizziness which was reported more frequently on lamotrigine than on placebo. There were no differences in abnormal haematological or biochemical findings between lamotrigine and placebo, and lamotrigine had no effect on plasma concentrations of concomitant AEDs. References 1 Meldrum B., Leach M. Rev Contemp Pharmacother 1994: 5: 107– 114. 2 Binnie CD, Debets RMC, Engelsman M., et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989: 4: 222– 9. 3 Schmidt D., Ried S., Rapp P. Add-on treatment with lamotrigine for intractable partial epilepsy: a placebo-controlled crossover trial. Epilepsia 1993: 34 (Suppl 2): 66. 4 Jawad S., Richens A., Goodwin G., Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989: 30: 356– 63. 5 Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990: 6: 221– 6. 6 Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993: 56: 448– 53. 7 Loiseau P., Yuen AWC, Duche B., Me'nager T., Arne-Bes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990: 7: 136– 45. 8 Smith D., Baker G., Davies G., Dewey M., Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993: 34 (2): 312– 22. 9 Messenheimer J., Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: A multicenter, placebo-controlled, double-blind, crossover trial. Epilepsia 1994: 35: 113– 21. 10 Matsuo F., Bergen D., Faught E., et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993: 43: 2284– 91. 11 Binnie CD, van Emde Boas W., Kasteleijn-Nolste-Trenite DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986: 27: 248– 54. 12 Jawad S., Yuen WC, Peck AW, et al. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987: 1: 194– 201. 13 Dreifuss FE. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981: 22: 489– 501. 14 Tassinari CA, Michelucci R., Ambrosetto G., Salvi F. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol 1987: 44: 907– 10. 15 Gram L., Wulff K., Rasmussen KE, et al. Valproate sodium: A controlled clinical trial including monitoring of drug levels. Epilepsia 1997: 18: 141– 8. 16 Harden CL, Zisfein J., Atos-Radzion EC, Tuchman AJ. Combination valproate-carbamazepine therapy in partial epilepsies resistant to carbamazepine monotherapy. J Epilepsy 1993: 6: 91– 4. 17 Clifford JS, Yuen AWC, Brodie MJ and the Lamictal Study Group Open multicentre trial of lamotrigine in patients with treatment resistant epilepsy withdrawing from add-on to lamotrigine monotherapy. Epilepsia 1994: 35 (Suppl 8): 31. Citing Literature Volume94, Issue4October 1996Pages 247-252 ReferencesRelatedInformation